Update:
We have extensively discussed numbers & MCaps up to last few asx events-
Taiwan, Italy (500 outlets), FdaOTC etc
Lets us add some "What If..." to latest
LiveCare LINK usa potential
My guestimate revenues from this WIN-WIN-WIN parnertship:
300,000 GPs (outlets) ,700 organisations, in 39 states of USA
(Keep in mind, Prizma is approved to combat covid19 in usa)
What if
A) # of Prizmas prsecribed/recommended/sold by all 300,000 GPs are:
1/day=75m
1/week=15.6m
1/month=3.6m
1/qtr=1.2 million Prizma
1/yr=0.3m
Say 1/qtr, 1.2 million Prizma for next 12 months, is my very low conservative pick.
B) Remote Patient Monitor
IF monthly RPMonitor fees are as follow:
U$/mth, annual, split 50/50
10,120, 60
*20, 240, $120* (What if this is the one...)
30,350,180,
60,720,360
C) Recurring Revenues =AxB
1.2m x $120 = U$240m
$240m looks a bit high?
How about
$120m?
$60$
$30m
Take your pick, my fellow LTHs, and do the MCaps estimates
@Galilee13Imo
This deal with LIVECARE has truly put Prizma and Gmed on USA map ( at least 39 states =)
NASDAQ, here we come!
ps
I encourage LTHs to extend your patience a bit longer, till you make a bag or two in next 3-6 months, no matter what your av price in.
Very exciting times ahead for a Israel medtech with global footprints!
I like to see a partnership with a PHARMACY chains in AMERICA in next few months
ROFL
.